Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,834 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Diseases, Genetic Clear all
Completed Not applicable Interventional

A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area

NCT05226143
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Gel Cream
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Not applicable Interventional

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00003538
View directory record Official record
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

NCT00630747
View directory record Official record
Conditions
Hunter Syndrome, Mucopolysaccharidosis II (MPS II)
Interventions
Idursulfase
Biological
Lead sponsor
Shire
Industry
Eligibility
5 Years and older · Male only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
16
States / cities
Phoenix, Arizona • Oakland, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BTL-785F Device for Improving the Structure of Facial Muscles

NCT05524740
View directory record Official record
Conditions
Wrinkle
Interventions
BTL-785-7
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

NCT03190174
View directory record Official record
Conditions
Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation
Interventions
Nab-Rapamycin, Nivolumab
Drug · Biological
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
12 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 17, 2026, 10:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774
View directory record Official record
Conditions
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions
Tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 3 Interventional Results available

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

NCT01005888
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline)
Biological · Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
16
States / cities
Scottsdale, Arizona • San Diego, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 17, 2026, 10:37 PM EDT
Completed No phase listed Observational

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

NCT00379678
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 17, 2026, 10:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

NCT00001885
View directory record Official record
Conditions
Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 10:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Studies in Alzheimer's Disease

NCT00001235
View directory record Official record
Conditions
Alzheimer's Disease, Nervous System Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Not applicable Interventional Results available

Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema

NCT01326910
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Colloidal Oatmeal, Topical Cream
Drug · Device
Lead sponsor
Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
Industry
Eligibility
6 Months to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Miamiville, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

NCT06015308
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Tdap vaccine, PPS vaccine
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 10:37 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

NCT00871208
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Altabax (R), Vehicle and Locoid lipocream (R)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
9 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 17, 2026, 10:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Combined Focused Ultrasound and Calcium Hydroxylapatitie Filler for Skin Laxity and Volume Restoration

NCT04176068
View directory record Official record
Conditions
Skin Laxity
Interventions
calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)
Combination Product
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 17, 2026, 10:37 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 10:37 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT06058156
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
SAR444656 (KT-474), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Scottsdale, Arizona • Boynton Beach, Florida • Doral, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 17, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

NCT03579875
View directory record Official record
Conditions
Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
Interventions
Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, Alemtuzumab, Melphalan
Drug · Device
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 17, 2026, 10:37 PM EDT
Not yet recruiting Phase 4 Interventional

Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

NCT06397781
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Skin Cleanser Combination No.1
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2031 – 2039
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 17, 2026, 10:37 PM EDT
Completed No phase listed Observational

Visual Function and Ocular Pigmentation in Albinism

NCT00001153
View directory record Official record
Conditions
Albinism, Albinism, Ocular, Albinism, Oculocutaneous
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1976 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 10:37 PM EDT
Completed No phase listed Observational

A Natural History Study of Sanfilippo Syndrome Type D

NCT05648851
View directory record Official record
Conditions
Sanfilippo Syndrome Type D
Interventions
Not listed
Lead sponsor
Phoenix Nest
Industry
Eligibility
12 Months and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 17, 2026, 10:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Sister Study: Genetic and Environmental Risk Factors for Breast Cancer

NCT00047970
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
35 Years to 74 Years · Female only
Enrollment
50,884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 17, 2026, 10:37 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

NCT05643872
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
PTX-022
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Brighton, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 17, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

NCT03835767
View directory record Official record
Conditions
Milk and/or Peanut Allergy
Interventions
Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk)
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 10:37 PM EDT
Recruiting Early Phase 1 Interventional

Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

NCT05649098
View directory record Official record
Conditions
Skin Diseases
Interventions
Dupilumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 17, 2026, 10:37 PM EDT